October 30, 2018
Dr Nobuaki Suzuki at Shire media seminar A hematology specialist called for careful consideration when using Chugai Pharmaceutical’s hemophilia treatment Hemlibra (emicizumab) in children as its additional indication could greatly expand its target patients in Japan. In a Q&A session...read more